Earnings call transcript: Swedish Orphan Biovitrum Q1 2026 shows strong growth

Swedish Orphan Biovitrum reported Q1 2026 revenue of SEK 7.0-7.2 billion, up 24% at constant exchange rates, with adjusted EBITDA margin improving to 38% from 36% and operating cash flow of SEK 1.1 billion. Growth was driven by ALTUVOCT (+186%), Gamifant (+47%), Aspaveli (+21% sequentially) and Doptelet (+44%), while the strategic portfolio rose 55% to 63% of revenue. Management kept full-year 2026 guidance unchanged for low-double-digit revenue growth and a mid-30s EBITDA margin, and the stock was up 0.05% pre-market.

Analysis

The interesting part here is not the quarter itself, but the shape of the next two years of cash conversion. Sobi is effectively turning into a launch-rollup story where the valuation should be driven more by execution on a handful of infant franchises than by the legacy base; that tends to create a steepening earnings curve once reimbursement inflects, but also a lot of quarterly noise from stocking, access, and geography. The market is likely underestimating how much of the current revenue mix is now self-reinforcing: each successful launch improves prescriber density and center relationships, which lowers future SG&A intensity per dollar of sales.

The key competitive dynamic is that the company’s growth is increasingly tied to rare-disease specialty centers, which are capacity-constrained rather than price-elastic. That makes this less vulnerable to broad macro healthcare pressure than peers, but more exposed to execution risk if a launch misses payer timing by even one quarter. The strongest second-order effect is that the new products should widen the moat around Sobi’s field force and KOL network, making it harder for later entrants to dislodge them once the prescribing habit forms.

The contrarian angle is that the market may be extrapolating the launch slope too linearly. Rare-disease launches often look better in the first 2-3 quarters because early adopters are concentrated, then decelerate as access broadens and the easy patients are captured; that argues for a more selective stance into any upside gap. Conversely, if the company clears the next wave of reimbursement/regulatory milestones in the next 60-120 days, the multiple could re-rate before the street fully models the incremental patient pool and the operating leverage from the broadened portfolio.

Key Decisions for Investors

• Go long Sobi on any post-earnings pullback over the next 1-2 weeks; risk/reward is attractive if the market is still discounting launch durability rather than the reimbursement pipeline. Use a tight stop if the stock loses post-print support, because the setup is execution-dependent.
• Add to a healthcare long book via SOBI equity or call spreads with a 3-6 month horizon; the catalyst stack is unusually dense, and upside can re-rate before sell-side numbers catch up. Prefer call spreads over outright calls to limit premium decay if launch momentum pauses.
• If available in the market, short a basket of higher-multiple orphan-drug names with slower launch cadence against SOBI as a relative-value pair. The thesis is that Sobi has better near-term organic growth visibility and more operating leverage than peers priced off longer-dated pipeline optionality.
• Take profits into the next reimbursement/regulatory headline if the stock has already re-rated 10-15%; the main risk is a classic rare-disease launch fade once early center uptake normalizes. Re-enter on any evidence of payer friction or launch slippage if the market overreacts.